Shares of Aclaris Therapeutics Inc. (NASDAQ:ACRS) rose 64% to $1.80 Tuesday on news that A-101, its topical treatment of verruca vulgaris, or common warts, met both the primary and all secondary efficacy endpoints of the phase III THWART-2 trial, the first of two pivotal studies intended to support an NDA filing for the drug, a high-concentration topical hydrogen peroxide solution. The other trial, THWART-1, is expected to read out in the fourth quarter.